POLICY & PRACTICE

Avandia Comes Under Fire

Public Citizen has petitioned the Food and Drug Administration to remove GlaxoSmithKline's rosiglitazone (Avandia) from the market because of unacceptable safety risks. The public interest group cited 14 cases of liver failure—including 12 deaths—in patients on the drug as the main reason for its petition; the cases were reported to the FDA's MedWatch program. "The scientific consensus against Avandia is overwhelming," said Dr. Sidney Wolfe, director of Public Citizen's Health Research Group. In response, GlaxoSmithKline issued a statement saying that as recently as July 2008, its external Hepatic Safety Board, which reviews adverse events, "continued to endorse a favorable hepatic safety profile for Avandia. ... The record of safety and effectiveness of Avandia is backed by one of the largest clinical trial programs (including 52,000 patients) ever undertaken for any medicine.

Diabetes Treatment Costs Rising ...

The cost of drugs to treat type 2 diabetes rose from \$6.7 billion to \$12.5 billion from 2001 to 2007, according to a study in the Archives of Internal Medicine. Using data from the National Disease and Therapeutic Index as well as the National Prescription Audit, the researchers also found that the average cost of a diabetes prescription had risen from \$56 in 2001 to \$76 in 2007. The authors, led by Dr. G. Caleb Alexander of the University of Chicago, attributed much of the cost increase to the rising use of newer medications, such as glitazones, exenatide, and newer insulins. "Although many of these newer therapies have made therapy more convenient and may have potentially lowered the risk of treatment-associated complications, further research of their longterm benefits is needed," the authors wrote, adding that "[s]ubstantial outcome differences would be needed to overcome the high cost of the newer drugs.'

... As Incidence Nearly Doubles

The rate of new diabetes cases increased by more than 90% over the last 10 years, according to a study by the Centers for Disease Control and Prevention. The CDC found that the incidence of diabetes among adults increased from 4.8 per 1,000 from 1995-1997 to 9.1 per 1,000 from 2005-2007. "This study demonstrates that we must continue to promote effective diabetes prevention efforts," said lead author Karen Kirtland, Ph.D. The incidence of new cases was highest in Puerto Rico, at 12.8 per 1,000, and lowest in Minnesota, at 5 per 1,000.

New Leaders at ATA

The American Thyroid Association installed a new president at its annual meeting in Chicago last month. Dr. Kenneth Burman, chief of the endocrine section at Washington (D.C.) Hospital Center is the association's new president. "It has been a privilege to be a member of the ATA since 1975, my most valued and important society [membership]," Dr. Burman said in a statement. Chosen as president-elect was Dr. Terry Davies, professor of medicine at the Mount Sinai School of Medicine, New York. —Joyce Frieden

INDEX OF ADVERTISERS

Amylin Pharmaceuticals, Inc. Byetta	18-20
Bayer HealthCare LLC	
A1CNow+	5
CONTOUR	24
Daiichi Sankyo, Inc.	
Welchol	12a-12d
Eli Lilly and Company	
Humalog Website	8
Glucagon	21
Merck & Co., Inc.	
Janumet	6a-6b, 7
Novo Nordisk Inc.	
NovoLog	10-12
Levemir	15-16
ResMed	
Corporate	9
sanofi-aventis U.S. LLC	
Lantus	3-4

CLASSIFIEDS

PROFESSIONAL OPPORTUNITIES



Marshfield Clinic.

Where the future of medicine lives.



Marshfield Clinic is a nationally recognized health care leader and innovator. We provide our physicians with the most advanced medical equipment and health information technology available today. And with a wide range of continuing education opportunities designed to serve the needs of physicians as well as patients.

Marshfield Clinic offers:

- A 100% endocrinology practice
- · EMR accessed with mobile PC at point of service
- The advantage of practicing where genetic research and educational opportunities
- · A community that offers affordable housing, excellent schools, plus proximity to excellent indoor and outdoor recreational activities
- A benefit package including a fully funded retirement plan, matching 401K plan, four weeks paid vacation, two weeks CME with up to \$5,800 allowance, generous

To learn more about an excellent opportunity, please contact: Mary Treichel, Physician Recruiter, Phone: 800-782-8581 extension 19774; Fax: 715-221-9779.



The Center for Endocrinology, Diabetes, and Metabolism of Childrens Hospital Los Angeles/ The Keck School of Medicine of USC is seeking a board-certified/board-eligible pediatric endocrinologist at the Assistant or Associate Professor level, interested in patient care, teaching, and clinical research. The division is comprised of 9 faculty members with a fellowship program and a large support staff, including 5 certified diabetes nurse educators. Childrens Hospital Los Angeles is a 300-bed free-standing pediatric academic center in the process of building a state-of-the-art inpatient facility and with a large pediatric training program, and affiliated with the Saban Research Institute. Interested applicants should contact Francine Kaufman, MD at : fkaufman@chla.usc.edu The University of Southern California is an equal opportunity/affirmative action employer.

Disclaimer

CLINICAL ENDOCRINOLOGY NEWS assumes the statements made in classified advertisements are accurate, but cannot investigate the statements and assumes no responsibility or liability concerning their content. The Publisher reserves the right to decline, withdraw, or edit advertisements. Every effort will be made to avoid mistakes, but responsibility cannot be accepted for clerical or printer errors.

Excellent Opportunity for Medical Director of Diabetes Institute in Orlando, Florida

Florida Hospital is excited to announce the expansion of the Florida Hospital Diabetes Institute ("FHDI"). We are seeking a top-tier physician to be Medical Director. The ideal candidate will lead our clinical team, continuing to build the reputation of the FHDI and to bring this multi-disciplinary center to the next level of care, commitment and recognition. This experienced and dynamic Medical Director will guide the clinical, operational, and research performance of the Institute.

Ideal Medical Director Attributes would include:

- *National recognition within the endocrinology medical community..
- *Board Certified in Diabetes, Endocrinology and Metabolism with
- 8-10 years of clinical experience.
- *Clinical research experience with peer review publishing.
- *Demonstrated competency with obtaining federal funding awards.
- *Dynamic energy and excellent communicator.
- *Experience with community speaking/grand rounds.
- *Experience with an academic setting.

Contact Jason Junker, Director of Physician Recruitment 407.200.2538 or Jason.Junker@flhosp.org



FARMINGTON, NM

San Juan Regional Medical Center in is recruiting for an Endocrinology/IM Physician to join a Hospital-employed, practice with inpatient and outpatient care with salary and productivity compensation, excellent benefits and relocation assistance. SJRMC is a level III trauma center with an Hospitalist program and New Mexico is a state with a low malpractice risk. The Four Corners area of New Mexico offers recreational activities including World-Class skiing, fly fishing, biking, golfing, hiking and more! Contact Terri Smith at 888-282-6591, Fax: 505-609-6681, tsmith@sjrmc.net www.sanjuanregional.com or www.sjrmcdocs.com